search
Back to results

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
rAd35 Env A
rAd5 Env A
rAd5 Env B
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV Infections focused on measuring HIV Preventive Vaccine

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Assessed by clinic staff as being "low risk" for HIV infection
  • Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site (CRS) and willing to be followed for the duration of the study
  • Able and willing to provide informed consent
  • Assessment of understanding, including the completion of a questionnaire before the first vaccination and demonstration of understanding for all questionnaire items answered incorrectly
  • Willing to receive HIV test results
  • Willing to discuss HIV infection risks, amenable to HIV risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required study visit
  • Willing to continue annual follow-up contact after the final study visit for a total of 5 years after study entry
  • In good general health, as shown by medical history, physical exam, and screening laboratory tests
  • Assessed by the clinic staff as having a low risk of HIV infection on the basis of sexual behaviors in the 12 months before study entry. More information on this criterion can be found in the protocol.
  • Adenovirus 5 nAb titer less than 1:18
  • Adenovirus 35 nAb titer less than 1:12
  • Hemoglobin greater than or equal to 11.0 g/dL for participants who were born female and greater than or equal to 13.0 g/dL for participants who were born male
  • White blood cell (WBC) count between 3,300 to 12,000 cells/mm^3
  • Total lymphocyte count greater than or equal to 800 cells/mm^3
  • Remaining differential either within site's normal range or with site physician approval
  • Platelet level between 125,000 to 550,000/mm^3
  • Alanine aminotransferase (ALT) less than or equal to 1.25 times the site's upper limit of normal
  • Negative HIV-1 and -2 blood test
  • Negative Hepatitis B surface antigen (HBsAg)
  • Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV test is positive
  • Normal urine test results
  • Participants who were born female must have a negative pregnancy test result before the first study vaccination
  • Participants who were born female must agree to use an effective form of contraception from at least 21 days before study entry until the last study visit. More information on this criterion can be found in the protocol.
  • Participants who were born female must agree not to seek pregnancy through alternative methods (e.g., artificial insemination, in vitro fertilization) until after the last study visit
  • If born male, must be fully circumcised (as documented at screening examination)

Exclusion Criteria:

  • Excessive daily alcohol use, frequent binge drinking, chronic marijuana abuse, or use of any other illicit drugs in the 12 months before study entry
  • History of newly acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B in the 12 months before study entry
  • Received non-HIV experimental vaccines in a previous vaccine trial in the 5 years before study entry
  • Received HIV vaccines in a prior HIV vaccine trial
  • Immunosuppressive medications received within 168 days before the first study vaccination
  • Blood products received within 120 days before the first study vaccination
  • Immunoglobulin received within 60 days before the first study vaccination
  • Live attenuated vaccines received within 30 days before the first study vaccination or scheduled within 14 days after injection
  • Investigational research agents received within 30 days before the first study vaccination
  • Intent to participate in another investigational drug study
  • Any vaccines that are not live attenuated vaccines and were received within 14 days before the first study vaccination
  • Allergy treatment with antigen injections within 30 days before the first study vaccination or scheduled within 14 days after the first vaccination
  • Current anti-tuberculosis (TB) prophylaxis or therapy
  • Clinically significant medical condition, abnormal physical examination findings, clinically significant abnormal laboratory results, or past medical history that may affect current health
  • Any medical, psychiatric, occupational, or other condition that would interfere with participation in the study
  • Serious adverse reactions to vaccines, including anaphylaxis and related symptoms (e.g., hives, respiratory difficulty, angioedema, abdominal pain). A person who had an adverse reaction to the pertussis vaccine is not excluded.
  • Autoimmune disease or immunodeficiency
  • Active syphilis infection
  • Asthma, other than mild well-controlled asthma. More information on this criterion can be found in the protocol.
  • Type 1 or type 2 diabetes mellitus, including cases controlled with diet alone. People with a history of gestational diabetes are not excluded.
  • Surgical removal of the thyroid or thyroid disease requiring medication in the 12 months before study entry
  • Angioedema in the 3 years before study entry or angioedema requiring medication in the 2 years before study entry
  • High blood pressure that is not well controlled or high blood pressure of 150/100 mm Hg or greater at study entry. More information on this criterion can be found in the protocol.
  • Body mass index (BMI) greater than or equal to 40, or BMI greater than or equal to 35 and two or more of the following conditions: age greater than 45, systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, current smoker, or known hyperlipidemia
  • Bleeding disorder (e.g., factor deficiency, coagulopathy, platelet disorder requiring special precautions)
  • Cancer. People with surgically removed cancer, that in the opinion of the investigator, is unlikely to recur during the study period are not excluded.
  • Seizure disorder. People with a history of seizures who have not required medications or had a seizure within the 3 years before study entry are not excluded.
  • Absence of the spleen
  • Psychiatric condition that makes study compliance difficult (e.g., people with psychoses in the 3 years before study entry, ongoing risk for suicide, history of suicide attempt in the 3 years before study entry)
  • Pregnant or breastfeeding
  • Has been circumcised within 90 days prior to first vaccination or displays evidence that surgical site is not fully healed

Sites / Locations

  • Alabama CRS
  • Bridge HIV CRS
  • The Hope Clinic of the Emory Vaccine Center CRS
  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
  • Columbia P&S CRS
  • New York Blood Center CRS
  • University of Rochester Vaccines to Prevent HIV Infection CRS
  • Vanderbilt Vaccine (VV) CRS

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

rAd35 Env A and rAd5 Env A

rAd35 Env A and rAd5 Env B

rAd35 Env A and rAd35 Env A

rAd5 Env A and rAd5 Env A

rAd5 Env A and rAd5 Env B

Arm Description

Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.

Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.

Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.

Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.

Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.

Outcomes

Primary Outcome Measures

Frequency and severity of local injection site reactogenicity signs and symptoms, including pain, tenderness, erythema, induration, and maximum severity of pain and/or tenderness
Frequency and severity of systemic reactogenicity signs and symptoms, including fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms
Frequency of adverse events (AEs) categorized by MedDRA body system, MedDRA preferred term, severity and assessed relationship to study products; detailed description of all AEs meeting DAIDS criteria for expedited reporting
Distribution of values of safety laboratory measures, including white blood cells (WBCs), neutrophils, lymphocytes, hemoglobin, platelets, and alanine aminotransferase (ALT) at baseline and at postvaccination follow-up study visits
Number of participants with early discontinuation of vaccinations and reason for discontinuation
Number of shared HIV epitopes targeted by T-cells
HIV-1-specific interferon gamma (IFN-y) ELISpot responses

Secondary Outcome Measures

Number of shared HIV epitopes targeted by T-cells
HIV-1-specific IFN-y ELISpot responses
Frequency of insert-specific CD4 and CD8 cells
Number of HIV epitopes targeted by T-cells
Functional spectrum of CD4 and CD8 cells by intracellular cytokine staining (ICS) assay for IFN-y, IL-2, and TNF-a
Binding and neutralizing antibody titers

Full Information

First Posted
March 26, 2010
Last Updated
October 13, 2021
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT01095224
Brief Title
Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
Official Title
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Regimens Utilizing Recombinant Adenovirus Serotype 35 (rAd35) With HIV-1 Clade A Env Insert and Recombinant Adenovirus Serotype 5 (rAd5) With HIV-1 Clade A or B Env Inserts in Healthy, HIV-1-Uninfected Adults
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and immune response of an adenovirus-based HIV-1 vaccine regimen that includes two vaccines given at different time points in HIV-uninfected adults.
Detailed Description
One approach to developing a preventive HIV vaccine includes the use of a prime-boost vaccine strategy. This type of strategy involves two vaccines, given sequentially at different time points. The goal is to stimulate different parts of the immune system and enhance the body's overall immune response to HIV. In this study, participants will receive two HIV vaccines 3 months apart. Heterologous-insert prime-boost vaccine regimens, which use the same gene from different HIV-1 subtypes, may be more effective than traditional homologous insert prime-boost vaccine regimens at eliciting immune responses directed at epitopes that are highly prevalent, possibly leading to a more effective immune system response to the vaccine. The purpose of this study is to assess the safety and immunogenicity of a heterologous-insert prime-boost HIV vaccine regimen that uses inserts from different HIV-1 subtypes and different adenovirus vectors. This study will enroll healthy, HIV-uninfected people. Participants will be randomly assigned to one of five study groups: Group 1 will receive the recombinant adenovirus serotype 35 (rAd35) Env A vaccine at baseline and the recombinant adenovirus serotype 5 (rAd5) Env A vaccine at Month 3. Group 2 will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3. Group 3 will receive the rAd35 Env A vaccine at baseline and at Month 3. Group 4 will receive the rAd5 Env A vaccine at baseline and at Month 3. Group 5 will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3. All vaccines will be injected into the upper arm. At both vaccination study visits, participants will undergo a physical exam, a medical and medication history review, a blood and urine collection, and questionnaires. Participants will receive counseling on HIV risk reduction and pregnancy prevention. After receiving the vaccine, participants will remain in the clinic for at least 30 minutes for observation and monitoring of side effects. For 3 days after each vaccination, participants will record their temperature and side effects in a symptom log. In addition to the vaccine study visits, other study visits will occur at Week 2, two weeks after the Month 3 visit, and at Months 4, 6, and 9, at which time various study procedures will be repeated. Participants will be contacted by study researchers once a year for 5 years for follow-up safety monitoring. Safety monitoring will not involve visiting a clinic except if a confirmatory HIV test is needed. Questions will assess health and adverse events. The primary objective of this study is to assess the safety and tolerability, as well as the ability, of a heterologous-insert prime-boost vaccine regimen using env inserts from different HIV-1 clades to increase T-cell responses. In addition, this study is evaluating the effectiveness of a heterologous-insert prime-boost and vector prime-boost vaccine regimen at increasing T-cell responses. The study will also compare the degree of polyfunctionality of insert specific T cells after vaccination within heterologous and homologous vector vaccine regimens.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
HIV Preventive Vaccine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Actual)

8. Arms, Groups, and Interventions

Arm Title
rAd35 Env A and rAd5 Env A
Arm Type
Experimental
Arm Description
Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
Arm Title
rAd35 Env A and rAd5 Env B
Arm Type
Experimental
Arm Description
Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
Arm Title
rAd35 Env A and rAd35 Env A
Arm Type
Experimental
Arm Description
Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
Arm Title
rAd5 Env A and rAd5 Env A
Arm Type
Experimental
Arm Description
Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
Arm Title
rAd5 Env A and rAd5 Env B
Arm Type
Experimental
Arm Description
Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
Intervention Type
Biological
Intervention Name(s)
rAd35 Env A
Other Intervention Name(s)
VRC-HIVADV027-00-VP
Intervention Description
1 x 10^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
Intervention Type
Biological
Intervention Name(s)
rAd5 Env A
Other Intervention Name(s)
VRC-HIVADV038-00-VP
Intervention Description
1 x 10^10 PU administered as 1 mL IM in deltoid
Intervention Type
Biological
Intervention Name(s)
rAd5 Env B
Other Intervention Name(s)
VRC-HIVADV052-00-VP
Intervention Description
1 x 10^10 PU administered as 1 mL IM in deltoid
Primary Outcome Measure Information:
Title
Frequency and severity of local injection site reactogenicity signs and symptoms, including pain, tenderness, erythema, induration, and maximum severity of pain and/or tenderness
Time Frame
Measured at baseline and Month 3
Title
Frequency and severity of systemic reactogenicity signs and symptoms, including fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms
Time Frame
Measured at baseline and Month 3
Title
Frequency of adverse events (AEs) categorized by MedDRA body system, MedDRA preferred term, severity and assessed relationship to study products; detailed description of all AEs meeting DAIDS criteria for expedited reporting
Time Frame
Measured at Month 9
Title
Distribution of values of safety laboratory measures, including white blood cells (WBCs), neutrophils, lymphocytes, hemoglobin, platelets, and alanine aminotransferase (ALT) at baseline and at postvaccination follow-up study visits
Time Frame
Measured at Month 9
Title
Number of participants with early discontinuation of vaccinations and reason for discontinuation
Time Frame
Measured at Month 9
Title
Number of shared HIV epitopes targeted by T-cells
Time Frame
Measured at 4 weeks following the final vaccination
Title
HIV-1-specific interferon gamma (IFN-y) ELISpot responses
Time Frame
Measured at 4 weeks following the final vaccination
Secondary Outcome Measure Information:
Title
Number of shared HIV epitopes targeted by T-cells
Time Frame
Measured at 4 weeks following the final vaccination
Title
HIV-1-specific IFN-y ELISpot responses
Time Frame
Measured at 4 weeks following the final vaccination
Title
Frequency of insert-specific CD4 and CD8 cells
Time Frame
Measured at 4 weeks following the final vaccination
Title
Number of HIV epitopes targeted by T-cells
Time Frame
Measured at 4 weeks following the final vaccination
Title
Functional spectrum of CD4 and CD8 cells by intracellular cytokine staining (ICS) assay for IFN-y, IL-2, and TNF-a
Time Frame
Measured at Month 9
Title
Binding and neutralizing antibody titers
Time Frame
Measured at baseline and at 4 weeks following the final vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Assessed by clinic staff as being "low risk" for HIV infection Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site (CRS) and willing to be followed for the duration of the study Able and willing to provide informed consent Assessment of understanding, including the completion of a questionnaire before the first vaccination and demonstration of understanding for all questionnaire items answered incorrectly Willing to receive HIV test results Willing to discuss HIV infection risks, amenable to HIV risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required study visit Willing to continue annual follow-up contact after the final study visit for a total of 5 years after study entry In good general health, as shown by medical history, physical exam, and screening laboratory tests Assessed by the clinic staff as having a low risk of HIV infection on the basis of sexual behaviors in the 12 months before study entry. More information on this criterion can be found in the protocol. Adenovirus 5 nAb titer less than 1:18 Adenovirus 35 nAb titer less than 1:12 Hemoglobin greater than or equal to 11.0 g/dL for participants who were born female and greater than or equal to 13.0 g/dL for participants who were born male White blood cell (WBC) count between 3,300 to 12,000 cells/mm^3 Total lymphocyte count greater than or equal to 800 cells/mm^3 Remaining differential either within site's normal range or with site physician approval Platelet level between 125,000 to 550,000/mm^3 Alanine aminotransferase (ALT) less than or equal to 1.25 times the site's upper limit of normal Negative HIV-1 and -2 blood test Negative Hepatitis B surface antigen (HBsAg) Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV test is positive Normal urine test results Participants who were born female must have a negative pregnancy test result before the first study vaccination Participants who were born female must agree to use an effective form of contraception from at least 21 days before study entry until the last study visit. More information on this criterion can be found in the protocol. Participants who were born female must agree not to seek pregnancy through alternative methods (e.g., artificial insemination, in vitro fertilization) until after the last study visit If born male, must be fully circumcised (as documented at screening examination) Exclusion Criteria: Excessive daily alcohol use, frequent binge drinking, chronic marijuana abuse, or use of any other illicit drugs in the 12 months before study entry History of newly acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B in the 12 months before study entry Received non-HIV experimental vaccines in a previous vaccine trial in the 5 years before study entry Received HIV vaccines in a prior HIV vaccine trial Immunosuppressive medications received within 168 days before the first study vaccination Blood products received within 120 days before the first study vaccination Immunoglobulin received within 60 days before the first study vaccination Live attenuated vaccines received within 30 days before the first study vaccination or scheduled within 14 days after injection Investigational research agents received within 30 days before the first study vaccination Intent to participate in another investigational drug study Any vaccines that are not live attenuated vaccines and were received within 14 days before the first study vaccination Allergy treatment with antigen injections within 30 days before the first study vaccination or scheduled within 14 days after the first vaccination Current anti-tuberculosis (TB) prophylaxis or therapy Clinically significant medical condition, abnormal physical examination findings, clinically significant abnormal laboratory results, or past medical history that may affect current health Any medical, psychiatric, occupational, or other condition that would interfere with participation in the study Serious adverse reactions to vaccines, including anaphylaxis and related symptoms (e.g., hives, respiratory difficulty, angioedema, abdominal pain). A person who had an adverse reaction to the pertussis vaccine is not excluded. Autoimmune disease or immunodeficiency Active syphilis infection Asthma, other than mild well-controlled asthma. More information on this criterion can be found in the protocol. Type 1 or type 2 diabetes mellitus, including cases controlled with diet alone. People with a history of gestational diabetes are not excluded. Surgical removal of the thyroid or thyroid disease requiring medication in the 12 months before study entry Angioedema in the 3 years before study entry or angioedema requiring medication in the 2 years before study entry High blood pressure that is not well controlled or high blood pressure of 150/100 mm Hg or greater at study entry. More information on this criterion can be found in the protocol. Body mass index (BMI) greater than or equal to 40, or BMI greater than or equal to 35 and two or more of the following conditions: age greater than 45, systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, current smoker, or known hyperlipidemia Bleeding disorder (e.g., factor deficiency, coagulopathy, platelet disorder requiring special precautions) Cancer. People with surgically removed cancer, that in the opinion of the investigator, is unlikely to recur during the study period are not excluded. Seizure disorder. People with a history of seizures who have not required medications or had a seizure within the 3 years before study entry are not excluded. Absence of the spleen Psychiatric condition that makes study compliance difficult (e.g., people with psychoses in the 3 years before study entry, ongoing risk for suicide, history of suicide attempt in the 3 years before study entry) Pregnant or breastfeeding Has been circumcised within 90 days prior to first vaccination or displays evidence that surgical site is not fully healed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xia Jin, MD, PhD
Organizational Affiliation
University of Rochester
Official's Role
Study Chair
Facility Information:
Facility Name
Alabama CRS
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Bridge HIV CRS
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
The Hope Clinic of the Emory Vaccine Center CRS
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30030
Country
United States
Facility Name
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115-6110
Country
United States
Facility Name
Columbia P&S CRS
City
New York
State/Province
New York
ZIP/Postal Code
10032-3732
Country
United States
Facility Name
New York Blood Center CRS
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
University of Rochester Vaccines to Prevent HIV Infection CRS
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Vanderbilt Vaccine (VV) CRS
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232-2582
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19627166
Citation
Vaine M, Lu S, Wang S. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs. 2009;23(3):137-53. doi: 10.2165/00063030-200923030-00001.
Results Reference
background
PubMed Identifier
18535580
Citation
Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008 Jun;14(6):623-8. doi: 10.1038/nm.f.1774.
Results Reference
background
PubMed Identifier
26475930
Citation
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.
Results Reference
derived

Learn more about this trial

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

We'll reach out to this number within 24 hrs